OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED) announced interim results from its ongoing Phase 1b trial investigating navicixizumab, OncoMed’s anti-DLL4/VEGF bispecific antibody ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian CancerOctober 20, 2018 6:30 AM Pre-Open Movers 10/18: (PTI) (ECYT) (ACHC) Higher; (TXT) (TCBI) (ACRX) Lower (more...)October 18, 2018 9:28 AM